Stay updated on Surufatinib & JS001 Combo in Advanced Solid Tumors Clinical Trial

Sign up to get notified when there's something new on the Surufatinib & JS001 Combo in Advanced Solid Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Surufatinib & JS001 Combo in Advanced Solid Tumors Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The study record for a Phase I trial combining surufatinib with JS001 is displayed, with details on the treatment arms, participant eligibility, study outcomes, and its Beijing location.
    Difference
    46%
    Check dated 2026-11-07T12:14:50.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The footer identifies the site revision as v3.8.0 instead of v3.7.2; the page still displays a 403 Forbidden error rather than the study record.
    Difference
    0.2%
    Check dated 2026-10-31T12:45:11.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    A site-wide NIH notice announces updates and explains the agency’s transition from “Artificial Intelligence” to “Super Intelligence” terminology. The clinical trial record remains inaccessible behind a 403 error.
    Difference
    1%
    Check dated 2026-10-24T12:37:58.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    The footer’s site revision marker changes from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-17T13:46:54.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The footer now identifies the ClinicalTrials.gov site revision as v3.7.1 instead of v3.7.0, while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-10T13:26:42.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    The study page now displays a 403 Forbidden error, replacing the previous study content with a generic error page and removing the surrounding navigation.
    Difference
    18%
    Check dated 2026-09-19T18:33:27.000Z thumbnail image

Stay in the know with updates to Surufatinib & JS001 Combo in Advanced Solid Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Surufatinib & JS001 Combo in Advanced Solid Tumors Clinical Trial page.